VARMX

HQ - Leiden

Summary

VarmX, a biotech company developing novel therapies for coagulation disorders, including treatments to bypass direct oral anticoagulants, particularly FXa inhibitors

Deals Overview

Total Deals1

Valued Deals1

Total Value£ 86 M

Avg. Deal Size£ 86 M

Market Context

Senior Management

John Glasspool
Chief Executive Officer